RT Journal Article
T1 A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
A1 Bergua, Juan M
A1 Montesinos, Pau
A1 Martinez-Cuadron, David
A1 Fernandez-Abellan, Pascual
A1 Serrano, Josefina
A1 Sayas, Maria J
A1 Prieto-Fernandez, Julio
A1 Garcia, Raimundo
A1 Garcia-Huerta, Ana J
A1 Barrios, Manuel
A1 Benavente, Celina
A1 Perez-Encinas, Manuel
A1 Simiele, Adriana
A1 Rodriguez-Macias, Gabriela
A1 Herrera-Puente, Pilar
A1 Rodriguez-Veiga, Rebeca
A1 Martinez-Sanchez, Maria P
A1 Amador-Barciela, Maria L
A1 Riaza-Grau, Rosalia
A1 Sanz, Miguel A
K1 FLAG-Ida
K1 Genetic risk
K1 Prognostic factors
K1 Relapsed-refractory acute myeloid leukaemia
K1 Salvage treatment
AB The combination of fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor (FLAG-Ida) is widely used in relapsed/refractory acute myeloid leukaemia (AML). We retrospectively analysed the results of 259 adult AML patients treated as first salvage with FLAG-Ida or FLAG-Ida plus Gentuzumab-Ozogamicin (FLAGO-Ida) of the Programa Español de Tratamientos en Hematología (PETHEMA) database, developing a prognostic score system of survival in this setting (SALFLAGE score). Overall, 221 patients received FLAG-Ida and 38 FLAGO-Ida; 92 were older than 60 years. The complete remission (CR)/CR with incomplete blood count recovery (CRi) rate was 51%, with 9% of induction deaths. Three covariates were associated with lower CR/CRi: high-risk cytogenetics and t(8;21) at diagnosis, no previous allogeneic stem cell transplantation (allo-SCT) and relapse-free interval <1 year. Allo-SCT was performed in second CR in60 patients (23%). The median overall survival (OS) of the entire cohortwas 07 years, with 22% OS at 5-years. Four independent variables wereused to construct the score: cytogenetics, FLT3-internal tandem duplica-tion, length of relapse-free interval and previous allo-SCT. Using this strati-fication system, three groups were defined: favourable (26% of patients),intermediate (29%) and poor-risk (45%), with an expected 5-year OS of52%, 26% and 7%, respectively. The SALFLAGE score discriminated a sub-set of patients with an acceptable long-term outcome using FLAG-Ida/FLAGO-Ida regimen. The results of this retrospective analysis should bevalidated in independent external cohorts
PB John Wiley & Sons
YR 2016
FD 2016-04-26
LK http://hdl.handle.net/10668/10029
UL http://hdl.handle.net/10668/10029
LA en
NO Bergua JM, Montesinos P, Martinez-Cuadrón D, Fernández-Abellán P, Serrano J, Sayas MJ, et al. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol. 2016 Sep;174(5):700-10
NO A grant of I Programa de Intensificación en Investigación 2015, Junta de Extremadura, and the “Fundación Española de Hematología (FEHH)”; “Red Temática de Investigación Cooperativa en Cáncer” grant (RD12/0036/0014). We thank Carlos Pastorini, Mar Benlloch, and María Dolores García for data management.
DS RISalud
RD Apr 8, 2025